$1.38
+0.01 (+0.73%)
Open$1.39
Previous Close$1.37
Day High$1.42
Day Low$1.30
52W High$2.23
52W Low$0.85
Volume—
Avg Volume352.8K
Market Cap29.88M
P/E Ratio—
EPS$-0.44
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,169.6% upside
Current
$1.38
$1.38
Target
$31.32
$31.32
$21.60
$31.32 avg
$37.71
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.32M | 9.26M | 9.19M |
| Net Income | 712.1K | 643.5K | 610.9K |
| Profit Margin | 7.6% | 7.0% | 6.7% |
| EBITDA | 971.8K | 983.2K | 961.2K |
| Free Cash Flow | 631.5K | 606.6K | 819.9K |
| Rev Growth | +16.1% | +5.9% | +8.5% |
| Debt/Equity | 1.16 | 1.10 | 1.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |